Streetbeat News

TSBX

Turnstone Biologics Corp.

Industry

Biotechnology

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Open

0.53

Mkt cap

12M

Volume

213K

High

0.54

P/E Ratio

-0.17

52-wk high

5.75

Low

0.51

Div yield

N/A

52-wk low

0.44

Lumentum Holdings Inc. (NASDAQ:LITE) shares surged 16.4% after reporting better-than-expected Q4 earnings and strong Q1 revenue guidance. Other notable pre-market movers include SciSparc Ltd. (NASDAQ:SPRC) up 90.1% after court approval for a merger, and Turnstone Biologics Corp. (NASDAQ:TSBX) down 40.5% after poor Q2 EPS results.

Portfolio Pulse from Avi Kapoor

August 15, 2024 | 10:32 am

Turnstone Biologics shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:25 pm

Turnstone Biologics (NASDAQ:TSBX) reported a Q2 EPS of $(0.92), missing the analyst consensus estimate of $(0.84) by 9.52%. This represents an 87.83% improvement over the $(7.56) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:13 pm

Turnstone Biologics Corp. (NASDAQ:TSBX) reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic colorectal cancer. The trial showed a 25% overall response rate and a 50% disease control rate in the first four evaluable patients. The treatment demonstrated favorable tolerability and manufacturing success.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:13 pm

The article highlights the performance of 12 health care stocks during Monday's after-market session. Larimar Therapeutics (LRMR) saw the highest gain with a 23.6% increase, while NovaBay Pharmaceuticals (NBY) experienced the largest decline, falling by 9.9%. The article also mentions earnings reports for several companies.

Portfolio Pulse from Benzinga Insights

May 20, 2024 | 8:31 pm

The article highlights the performance of 12 healthcare stocks during Thursday's after-market session. Notable gainers include Scorpius Holdings (AMEX:SCPX), Kintara Therapeutics (NASDAQ:KTRA), and Doximity (NYSE:DOCS). Significant losers include TFF Pharmaceuticals (NASDAQ:TFFP), OptiNose (NASDAQ:OPTN), and Turnstone Biologics (NASDAQ:TSBX).

Portfolio Pulse from Benzinga Insights

May 16, 2024 | 8:31 pm

Turnstone Biologics (NASDAQ:TSBX) reported a Q1 EPS loss of $(0.85), missing the consensus estimate of $(0.78) by 8.97%.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 9:05 pm

Turnstone Biologics (NASDAQ:TSBX) reported a Q4 EPS loss of $(0.73), surpassing the analyst consensus estimate of $(0.86) by 15.12%.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 9:14 pm

In Tuesday's after-market session, several healthcare stocks showed significant movement. Etao International Co led the gainers with a 249.4% increase, while Aquestive Therapeutics experienced the largest decline among the losers at 11.4%. Taysha Gene Therapies reported Q4 earnings, contributing to a 29.36% rise in its stock. Other notable movers include Moleculin Biotech, Turnstone Biologics, and Enveric Biosciences on the gainers' side, and Trxade Health, Ontrak, and Virpax Pharmaceuticals among the losers.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 9:34 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Psyence Biomedical led the gainers with a 137.8% increase, while Amylyx Pharma saw the largest decline among the losers, dropping 81.5%. Other notable movers included Ainos, Mira Pharmaceuticals, and Joint, with substantial gains, and Immuron, Jin Medical International, and eFFECTOR Therapeutics among the losers.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.